Ozempic and Wegovy both contain semaglutide but are dosed differently for diabetes and weight management. Here is how their escalation schedules, max doses, and pen systems compare.
Ozempic and Wegovy are both manufactured by Novo Nordisk and contain the same active ingredient: semaglutide. The critical difference is their FDA-approved indication. Ozempic is approved for type 2 diabetes management. Wegovy is approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related health condition.
Because they target different conditions, their dosing protocols diverge significantly. Ozempic reaches a lower maximum dose because the primary goal is blood sugar control. Wegovy escalates to a higher maximum dose because clinical trials showed that greater weight loss required more medication.
Ozempic follows a three-step escalation over eight or more weeks:
Weeks 1-4: 0.25 mg weekly (initiation) Weeks 5-8: 0.5 mg weekly (first maintenance level) Weeks 9+: 1.0 mg weekly (standard maintenance) Optional: 2.0 mg weekly (maximum, if additional control needed)
The standard maintenance dose is 1.0 mg per week. The 2.0 mg dose was added in a later FDA approval for patients who need further A1C reduction. Many diabetes patients achieve adequate blood sugar control at 0.5 mg or 1.0 mg and never escalate to 2.0 mg.
Ozempic pens come in two fixed-dose versions: a 0.25 mg/0.5 mg pen and a 1.0 mg pen. The 2.0 mg dose uses its own dedicated pen.
Wegovy uses a five-step escalation over sixteen weeks to reach the full weight management dose:
Weeks 1-4: 0.25 mg weekly Weeks 5-8: 0.5 mg weekly Weeks 9-12: 1.0 mg weekly Weeks 13-16: 1.7 mg weekly Weeks 17+: 2.4 mg weekly (maintenance)
The maintenance dose of 2.4 mg is 20% higher than the maximum Ozempic dose and significantly higher than the standard Ozempic maintenance of 1.0 mg. The additional escalation steps at 1.7 mg and 2.4 mg are unique to Wegovy.
Each Wegovy dose level has its own color-coded, single-use, prefilled pen. Patients receive a new box of pens each month corresponding to their current escalation step.
Maximum dose: Ozempic tops out at 2.0 mg. Wegovy reaches 2.4 mg.
Escalation steps: Ozempic has 3 steps (plus optional 2.0 mg). Wegovy has 5 steps.
Time to maintenance: Ozempic reaches standard maintenance in 8 weeks. Wegovy takes 16 weeks.
Pen system: Ozempic pens are multi-dose with a dial selector. Wegovy pens are single-use with a fixed dose.
Insurance coverage: Ozempic is widely covered under diabetes formularies. Wegovy coverage for weight management is more limited and often requires prior authorization.
Off-label use: Ozempic is frequently prescribed off-label for weight loss because it is more widely available and covered by insurance. However, patients using Ozempic for weight loss typically do not reach the 2.4 mg dose that produced the strongest weight loss results in Wegovy clinical trials.
Compounded semaglutide, dispensed in multi-dose vials, is not brand-specific. Your provider prescribes a milligram dose, and you draw the corresponding number of units from your vial using a U-100 insulin syringe. This means compounded semaglutide patients can follow either an Ozempic-style or Wegovy-style escalation depending on their treatment plan.
The conversion formula remains the same regardless of which escalation schedule you follow: units = (dose in mg / concentration in mg per mL) x 100. Whether your target dose is 1.0 mg (Ozempic-style maintenance) or 2.4 mg (Wegovy-style maintenance), the math works identically. Your provider determines the right escalation schedule and maximum dose based on your individual health profile and treatment goals.
There's an easier way
We handle everything — the prescription, the right dose, and shipping straight to your door. No math, no hassle.
Get Started2-min quiz · Free consultation · No commitment
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.